Low PBRM1 identifies tumor progression and poor prognosis in breast cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 8, 2015, Pages 9307-9313

  Mo, Dan ^a   Li, Chunhong ^b   Liang, Junrong ^a   Shi, Qunfeng ^a   Su, Naiwei ^a   Luo, Shuyou ^a   Zeng, Tian ^a   Li, Xinning ^a  

^a Guangxi Zhuang Autonomous Region Institute of Metrology and Test   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; PBRM1; Prognosis

Indexed keywords

NUCLEAR PROTEIN; PBRM1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

BREAST; BREAST TUMOR; DISEASE COURSE; FEMALE; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS;

BIOMARKERS, TUMOR; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 85012994869     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Stuckey A. Breast cancer: epidemiology and risk factors. Clin Obstet Gynecol 2011; 54: 96-102.
2. Saad ED, Katz A and Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 2010; 28: 1958-1962.
3. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL and Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003; 100: 10393-10398.
4. Reisman D, Glaros S and Thompson EA. The SWI/SNF complex and cancer. Oncogene 2009; 28: 1653-1668.
5. Thompson M. Polybromo-1: the chromatin targeting subunit of the PBAF complex. Biochimie 2009; 91: 309-319.
6. Ye K, Schulz MH, Long Q, Apweiler R and Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 2009; 25: 2865-2871.
7. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA and Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
8. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, Greenman C, Hardy C, Jia M, Latimer C, Lau KW, Marshall J, McLaren S, Menzies A, Mudie L, Stebbings L, Largaespada DA, Wessels LF, Richard S, Kahnoski RJ, Anema J, Tuveson DA, Perez-Mancera PA, Mustonen V, Fischer A, Adams DJ, Rust A, Chan-On W, Subimerb C, Dykema K, Furge K, Campbell PJ, Teh BT, Stratton MR and Futreal PA. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469: 539-542.
9. Pawlowski R, Muhl SM, Sulser T, Krek W, Moch H and Schraml P. Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer 2013; 132: E11-17.
10. Xia W, Nagase S, Montia AG, Kalachikov SM, Keniry M, Su T, Memeo L, Hibshoosh H and Parsons R. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res 2008; 68: 1667-1674.
11. Hohmann AF and Vakoc CR. A rationale to target the SWI/SNF complex for cancer therapy. Trends Genet 2014; 30: 356-363.
12. Phelan ML, Sif S, Narlikar GJ and Kingston RE. Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. Mol Cell 1999; 3: 247-253.
13. Lu P and Roberts CW. The SWI/SNF tumor suppressor complex: Regulation of promoter nucleosomes and beyond. Nucleus 2013; 4: 374-378.
14. Huang L, Peng Y, Zhong G, Xie W, Dong W, Wang B, Chen X, Gu P, He W, Wu S, Lin T and Huang J. PBRM1 suppresses bladder cancer by cyclin B1 induced cell cycle arrest. Oncotarget 2015; 6: 16366-78.
15. Xiao X, Tang C, Xiao S, Fu C and Yu P. Enhancement of proliferation and invasion by MicroRNA-590-5p via targeting PBRM1 in clear cell renal carcinoma cells. Oncol Res 2013; 20: 537-544.
16. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani P, Offerhaus GJ, Roa JC, Roberts LR, Gores GJ, Popescu I, Alexandrescu ST, Dima S, Fassan M, Simbolo M, Mafficini A, Capelli P, Lawlor RT, Ruzzenente A, Guglielmi A, Tortora G, de Braud F, Scarpa A, Jarnagin W, Klimstra D, Karchin R, Velculescu VE, Hruban RH, Vogelstein B, Kinzler KW, Papadopoulos N and Wood LD. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013; 45: 1470-1473.
17. Nam SJ, Lee C, Park JH and Moon KC. Decreased PBRM1 expression predicts unfavorable prognosis in patients with clear cell renal cell carcinoma. Urol Oncol 2015; 33: 340.e9-340.e16.
18. Kim JY, Lee SH, Moon KC, Kwak C, Kim HH, Keam B, Kim TM and Heo DS. The impact of PBRM1 expression on prognostic and predictive marker in metastatic renal cell carcinoma. J Urol 2015; [Epub ahead of print].